scholarly journals Male breast cancer: a 5-year experience from a State Cancer Institute

2021 ◽  
Author(s):  
Shashi Singh Pawar ◽  
Manish Kumar ◽  
Kunal Kishor ◽  
Nadeem Ahmad ◽  
Sanjeet Kumar Singh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Ductal Carcinoma ◽  
Radical Mastectomy ◽  
Female Breast Cancer ◽  
Male Breast ◽  
Biological Behavior ◽  
Clinicopathological Profile ◽  
Her 2 ◽  
Male Patients

Background: Male breast cancer (MBC) is an uncommon malignancy accounting for <1% of all cancers in men and <1 % of overall breast cancer cases. Although there are many similarities between MBC and female breast cancer (FBC), they are not identical in clinical behaviour. There is need to understand the exact biological behavior of MBC.Methods: A retrospective observational study was done at State Cancer Institute, IGIMS, Patna which included all MBC patients registered during a 5-year study period (January 2016 to April 2021). 16 consecutive cases of MBC were identified and their detailed clinicopathological profile was analyzed.Results: MBC accounted for 1.10% of the total breast cancer cases. The median age of presentation was 58 years. Most common presentation was lump. Invasive ductal carcinoma (IDC) was most common histology. Majority of the patient presented to us in advanced stage. Estrogen receptor (ER)/progesterone receptor (PR) status was found to be positive in 12 patients. HER-2/neu receptor was positive in 4 patients. 2 patients had triple negative disease (TNBC) status. Surgery in the form of modified radical mastectomy (MRM) was done in 10 patients. All patients received adjuvant therapy as per NCCN guidelines.Conclusions: MBC is rare disease presenting at a relatively early age in Indian male patients. Most of them have positive ER/PR status. As outcomes have not improved comparatively, there is a need to evolve separate guidelines for MBC.

scholarly journals Management and Outcomes of Male Breast Cancer in Zaria, Nigeria

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Adamu Ahmed ◽  
Yahaya Ukwenya ◽  
Adamu Abdullahi ◽  
Iliyasu Muhammad
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Advanced Disease ◽  
Radical Mastectomy ◽  
Male Breast ◽  
Tumor Diameter ◽  
Axillary Lymph ◽  
Breast Cancers ◽  
Modified Radical Mastectomy ◽  
Male Patients

Male breast cancer is an uncommon disease accounting for only 1% of all breast cancers. We present the evaluation, treatment and outcome of male patients seen with breast cancer in our institution. Male patients that had histological diagnosis of breast cancer from 2001 to 2010 were retrospectively evaluated. After evaluation patients were treated with modified radical mastectomy. Combination chemotherapy was given to patients with positive axillary lymph nodes. Radiotherapy and hormonal therapy were also employed. There were 57 male patients with breast cancer which accounted for 9% of all breast cancers seen during the study period. Their mean age was 59 ± 2.3 years. The mean tumor diameter was 13 ± 2.5 cm. Fifty three (93%) patients presented with advanced disease including 15 with distant metastasis. Four patients with stage II disease were treated with modified radical mastectomy, chemotherapy and tamoxifen. Of the 30 patients with sage III disease that had modified radical mastectomy, complete axillary clearance and tumor free margins were achieved in 25. Overall 21 (36.8%) patients were tumor free at one year. Overall 5-year survival was 22.8%. In conclusion, male patients with breast cancer present with advanced disease which is associated with poor outcome of treatment.

A comparative analysis of angiogenesis between male and female breast cancers

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 21101-21101
Author(s):  
R. Bakkar ◽  
Z. Nahleh ◽  
H. Bui ◽  
S. Samaan ◽  
J. Sanders ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Median Survival ◽  
Ductal Carcinoma ◽  
Stage Iv ◽  
Female Breast Cancer ◽  
Male Breast ◽  
Breast Cancers ◽  
Therapeutic Modalities ◽  
Female Breast ◽  
Male Patients

21101 Background: Tumor angiogenesis and vascularization are essential for the growth and metastasis of tumors. VEGF-C expression and peritumoral lymphocyte density (PLD) are markers of angiogenesis. They have been correlated with poor prognosis in female breast cancer (FBC). The purpose of this study is to characterize VEGF-C expression and PLD in MBC and correlate with FBC specimens. Method: We reviewed records of patients diagnosed with MBC and FBC at the Cincinnati VAMC, from 1989 to 2006. Pathology slides were retrieved. We used VEGF-C (Host Rabbit, PAD: Z-CVC7) . Imunohistochemical stains of VEGF-C were given scores of 0 to 3+ based on nuclear stains. PLD was analyzed based on the number of lymphocyte cells surrounding the tumor; score of 0 to 3+. Slides were reviewed independently by two pathologists. Results: We found nine MBC cases and selected 9 FBC cases. Mean age was 72 in the male patients and 62 in the females. Stages of disease were distributed as follows in MBC versus FBC, 11% versus 22% stage 0, 23% versus 23% stage I, 44% versus 44% stage II, and 22% versus 11% stage IV. Ductal carcinoma was the predominant histology in 88% of FBC and 88% MBC. Other histological types included papillary (1 MBC) and lobular (1 FBC). Among the invasive MBC tumors , 75 % were ER+/PR +, 13% ER+/PR-, and 12% ER -/PR- , compared to 72 % ER+/PR+, 14% ER+/PR-, and 14% ER-/PR- in FBC. Eight out of the 9 MBC cases (89%) stained positive for VEGF-C expression, compared to one FBC case (11%). The 1 male breast intraductal carcinoma was positive for VEGF-C expression, compared to none of the two intraductal FBC. PLD was more intense in male than female tumors : score 0 or 1+: 44% in MBC versus 67% in FBC , score 2+: 22% in MBC Versus 22% in FBC, and score 3+: 22% in MBC versus 11% in FBC. VEGF-C expression did not seem to correlate with ER/PR status. The median survival for patients with MBC was 4.5 years and for patients with FBC 6.9 years. Conclusion: VEGF-C expression and PLD were more pronounced in MBC versus FBC. This finding may correlate with more aggressive behavior of breast tumor cells in male patients, more intense angiogenic reaction and lower median survival. Further studies are warranted to further elucidate the role of angiogenesis in male breast cancer and explore potential antiangiogenic therapeutic modalities. No significant financial relationships to disclose.

scholarly journals Rare Case of Male Breast Cancer and Axillary Lymphoma in the Same Patient: An Unique Case Report

2011 ◽  
Vol 2011 ◽  
pp. 1-4 ◽  
Author(s):  
Emiliano Sordi ◽  
Katia Cagossi ◽  
Maria Grazia Lazzaretti ◽  
Daniel Gusolfino ◽  
Fabrizio Artioli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Ductal Carcinoma ◽  
Malignant Lesion ◽  
Gene Mutations ◽  
Radical Mastectomy ◽  
Simultaneous Presentation ◽  
Needle Aspiration ◽  
Male Breast ◽  
First Case

Breast cancer in men is uncommon, and even more rare is the simultaneous presentation of two different malignancies. A 39-year-old man was diagnosed with both breast cancer and axillary lymphoma. Familiar history revealed that his mother died because of breast cancer. The patient underwent fine needle aspiration leading to the diagnosis of malignant lesion. Modified radical mastectomy was performed. Histology revealed an infiltrating ductal carcinoma 2.8 cm wide, grade 2, with vascular and lymphatic invasion. Surprisingly, one of the second level nodes was confirmed as a high-grade large B cell non-Hodgkin's lymphoma. No family inheritance or gene mutations (BRCA 1 and 2) were found. The patient underwent local radiotherapy, followed by 6 chemotherapy courses (RCHOP) and treatment with tamoxifen 20 mg/daily. To our knowledge, this is the first case reported in literature of male breast cancer and axillary lymphoma simultaneously confirmed in the same patient.

scholarly journals Alcohol and tobacco induced infiltrating ductal carcinoma male: a case report

2019 ◽  
Vol 7 (2) ◽  
pp. 613
Author(s):  
Akhila Janga Yadav ◽  
Bhavana Pamulapati Chowdary ◽  
Divya Bharathi Jekkula Yadav ◽  
Rajender Penthala ◽  
Vineeth Bonkuri
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Ductal Carcinoma ◽  
Epidemiological Studies ◽  
Female Breast Cancer ◽  
Nodal Metastasis ◽  
Male Breast ◽  
Chewing Tobacco ◽  
Mortality And Morbidity ◽  
Infiltrating Ductal Carcinoma

Male breast cancer is a rare cancer that forms in the breast tissue of men, it accounts for 1% of all the cancers in men. Recent epidemiological studies suggest that the incidence of MBC is increasing by 1.1% per year.  Due to lack of knowledge and awareness, MBC cases are diagnosed lately, mostly during stages III /IV. Early detection and reduction of mortality and morbidity related to male breast cancer is essential. The present article provides a detailed study of a patient with Infiltrating ductal carcinoma, grade III with regional nodal metastasis and the patient is positive for both oestrogen and progesterone receptors. In this case the patient is alcoholic and had habit of chewing tobacco since childhood and one of the patient’s relative had female breast cancer. These are the probable risk factors in this particular case. The better knowledge regarding the male breast carcinoma can be obtained through the thorough study of the available male breast cases.

Retrospective analysis on patients with male breast cancer

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 19681-19681
Author(s):  
A. M. Alvarez ◽  
M. N. Gandur Quiroga ◽  
G. Cinat ◽  
J. Iturbe ◽  
T. Said Nissi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Ductal Carcinoma ◽  
Lobular Carcinoma ◽  
Radical Mastectomy ◽  
Male Breast ◽  
History Of ◽  
The Media ◽  
Histological Characteristics ◽  
Breast Lumps

19681 Background: Male breast cancer is uncommon, 1%(0.7 %)of all breast cancer. Nevertheless, the incidence has climbed 26% over the past 25 years. Objetive: Analyze the form of presentation and clinical evolution of patients with male breast cancer studied from 1977 to 2005. Methods: From 1977 to 2005 53 charts were analyzed: age, clinical presentation, stage (st), histological characteristics and nodal involvement. Results: Age: 33 years to 83 years (median= 59 years). Mean durations of symptoms before presentations: 11 months (m) (range 1 - 84 m.) . Forty-six (86.7%) patients (pts) had history of breast lumps, 9 (17%) were painful. Skin involvement and ulceration were present in 5 (9.43%) and 4 (7.54 %) respectively. One case of bilateralism was found. Seven (13.2%) st. I; 18 (33.96%) st. II; 20 (37.73%) st. III and 7 (13.2%) st. IV. Radical mastectomy was done in 41 pts (77.35%). Invasive ductal carcinoma was the most common histological type in 45 (84.9%). One case of lobular carcinoma was found. 60.4% of tumours expressed hormonal receptor. Adyuvant treatment: Adriamycin-based chemotherapy in 20 pts and CMF in 8 pts. Hormonotherapy was offered in 10 (19%) pts of the previous group, radiotherapy to 12 pts. twenthy pts (37.73%) presented recurrence; most common was bone in 10. The st. I and II estimated 5-year survival rate was 68% IC 95% (44–84%), st. III was 44% IC 95% (23 - 67%), st. IV (median = 24 m) with range (16 - 56 m). The 72% IC 95% (48–88%) patients st. I and II was free of disease at the 5-years, st. III was free 24% IC 95% (9–49%), st. IV (median = 7,5 m) with range (7–14 m). Conclusions: The media age at diagnosis was 59 years (10 years less than the international bibliography). (IB). Our group had longer time to presentation: 11 vs. 6 m., (IB) and most of them where in st. III. Hormonal receptore were positive in 60%. No significant financial relationships to disclose.

scholarly journals Male breast cancer – how to treat?

2007 ◽  
Vol 10 (8) ◽  
Author(s):  
E. D. Rossmann ◽  
A. Liljegren ◽  
J. Bergh
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Radical Mastectomy ◽  
Breast Cancer Diagnosis ◽  
Male Breast ◽  
Aggressive Disease ◽  
Metastatic Setting ◽  
Her 2 ◽  
Low Incidence ◽  
Multimodal Management

AbstractTreatment principles of breast cancer in males are derived from studies performed among females, while the low incidence in males has so far precluded such studies. The therapy recommendations for males therefore lack the solid evidence, frequently present for females with breast cancer. The primary breast cancer diagnosis in males is not infrequently in stage III/IV and at higher age, thereby requiring multiprofessional and multimodal management including preoperative therapy and adjuvant therapies based on the tumour’s biological characteristics and the clinical circumstances. The majority of male breast cancer tumours are oestrogen-receptor positive and adjuvant/neoadjuvant tamoxifen is therefore recommended, surgery is frequently radical mastectomy and adjuvant radiotherapy should likely be used on wider indications. Chemotherapy should be considered both in the adjuvant and metastatic setting for receptor-negative cancers and for patients with biologically aggressive disease. Trastuzumab should be offered to patients with Her-2/neu-positive disease, while the use of aromatase inhibitors is more uncertain due to differences in the hormonal environment in males.

scholarly journals Survival Outcomes in Male Breast Cancer – A Single Institution Experience

2018 ◽  
Vol 3 (4) ◽  
pp. 71
Author(s):  
Nisha Hariharan
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Treatment Guidelines ◽  
Ductal Carcinoma ◽  
Radical Mastectomy ◽  
Male Breast ◽  
Survival Outcomes ◽  
Breast Cancers ◽  
Breast Cancer Patients

Introduction: Male breast cancer is an uncommon entity. Due to the scarce numbers, treatment protocolshave largely been extrapolated from available evidence for female breast cancers.Methods: We analysed the clinicopathological features and survival outcomes for male breast cancer patients treated at our institute between January 2010 and June 2016.Results: Of the 5534 women treated at our institute, we screened 40 male breast cancers of whom 33 had available follow up data and were included in the present analysis. Male breast cancer constituted 0.7% of all breast cancers. The median age was 60 years and the median tumor size was 3cm with 66% of patients having nodal disease at presentation. Invasive ductal carcinoma was the most common histology and 97% were hormone receptor positive. Most of the patients (87.8%) underwent an upfront modified radical mastectomy. With a median follow up of 36 months, 10 patients experienced recurrences all of which were distant metastasis (3 to the bone, 1 to the brain, and 6 had visceral metastasis). Of these, 7 patients succumbed to the disease. The 3-year overall survival was 78.7 %.Conclusion: Male breast cancer is a rare clinical entity and current treatment guidelines follow those for women. Due to the lack of awareness, men often present to clinics at an advanced stage. Social support targeted at improving awareness and access to treatment could improve outcomes in this cohort.  

scholarly journals Clinicopathologic characteristics and prognosis for male breast cancer compared to female breast cancer

2022 ◽  
Vol 12 (1) ◽  
Author(s):  
Nan Yao ◽  
Wenzai Shi ◽  
Tong Liu ◽  
Sarah Tan Siyin ◽  
Weiqi Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Competing Risks ◽  
Male Breast Cancer ◽  
Cox Regression ◽  
Female Breast Cancer ◽  
Male Breast ◽  
Limited Information ◽  
Female Breast ◽  
Her 2

AbstractMale breast cancer (MBC) is rare. Due to limited information, MBC has always been understudied. We conducted a retrospective population-based cohort study using data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program. The clinical and biological features of female breast cancer (FBC) patients were compared with MBC patients. Cox regression models and competing risks analyses were used to identify risk factors associated with cancer-related survival in MBC and FBC groups. Results showed that MBC patients suffered from higher TNM stages, tumor grades, and a higher percentage of hormone receptor-positive tumors, compared with FBC patients (all p < 0.05). In addition, the breast tumor locations varied a lot between males and females (p < 0.05). FBC patients were associated with superior overall survival than MBC patients. Results from multivariate cox regression and competing risks analyses showed age, race, T, N, M-stages, tumor grades, estrogen receptor (ER)/progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER-2) overexpression were independent prognosis factors in FBC patients (all p < 0.05). MBC patients had similar risk factors to FBC patients, but PR and HER-2 status did not independently influence survival (all p > 0.05). Tumor location was an independent prognostic factor for both gender groups.

Male breast cancer retrospective institution review of a 17-year period

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e11638-e11638
Author(s):  
C. Rodriguez Franco ◽  
D. Aguiar Bujanda ◽  
S. Saura Grau ◽  
U. Bohn Sarmiento ◽  
J. Aguiar Morales
Keyword(s):  
Breast Cancer ◽  
Cancer Progression ◽  
Male Breast Cancer ◽  
Ductal Carcinoma ◽  
Bilateral Breast Cancer ◽  
Radical Mastectomy ◽  
Male Breast ◽  
Good Survival ◽  
Histologic Subtype ◽  
History Of

e11638 Background: Male breast cancer (MBC) is a very uncommon illness relative to female breast cancer (FBC) The are some differences between both that could influence the management, like gene expression, hormonal enviroment and anatomy of the gland. Methods: Retrospective review of patients diagnosed in a seventeen year period (1990–2007). Results: There were 22 male patients diagnosed in our institution with a median age of 62.4 years (range 34 to 83 years) during the period. One had bilateral breast cancer. Stage of disease was I-II in 13 patients (59%), III in 8 patients (36%), and IV in 1 patient (5%). Five patients (22.7%) had familiar history of breast cancer and 3 patients (13%) had familiar history of other kind of neoplasias. Hormonal receptor were positive in thirteen patiens (59%) and 5 were unknown (23%). Ductal carcinoma was the predominant histologic subtype with 17 patients (77%). Other types were pleomorfic, mucoid and papilar carcinoma (one each type) and 3 patients with intrapapilar carcinoma with microinfiltration. Eleven of 20 patologic available axilla had node positive (55%). Grade were I in 3 patients (13%), II in 4 patients (18%), III in 8 (37%) and undefined in in 7 (32%). Surgery was the initial treatment in 18 patients (81%), just 2 of them performing tumorectomy and the other 16 radical mastectomy. 3 patients receive neoadyuvant chemotherapy with 1 complete response and one partial response. 13 patients (59%) received adjuvant radiotherapy (RT) and 17 (77%) adjuvant hormonal therapy (HT) mostly of them with tamoxifen (14/17) and the others 3 patients with aromatase inhibitors. Adjuvant chemotherapy was used in 9 (41%) patients with an antracycline regimen. With a median follow-up of 78 months (range 7–125), overall survival was 77 % with 3 patients died with progression disease and two patients died because of intercurrent illness without evidence of cancer progression. Regarding to our population area we had an incidence of 0.96/100.000 inhabitants during this 17 year period. Conclusions: MBC in our area are in the upper limit of occidental countries incidence. Most cases can be treated with radical intention with surgery (mostly radical) and adjuvant treatment with a good survival percentage. We manage MBC like we do FBC because of absence of clinical randomized trial specific for MBC. No significant financial relationships to disclose.

Changes in Male Breast Cancer over a 30-Year Period

2008 ◽  
Vol 74 (8) ◽  
pp. 707-712 ◽  
Author(s):  
Nicholas Paul Schaub ◽  
Nell Maloney ◽  
Heather Schneider ◽  
Eric Feliberti ◽  
Roger Perry
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Ductal Carcinoma ◽  
Radical Mastectomy ◽  
Retrospective Chart Review ◽  
Male Breast ◽  
Breast Cancers ◽  
Breast Cancer Patients ◽  
Lymph Node Mapping ◽  
Presenting Symptoms

Male breast cancer is a rare clinical entity accounting for approximately 1 per cent of all breast cancers. The present study investigated changes in patient characteristics, disease patterns, treatment, and outcomes over a 30-year period. A retrospective chart review was performed on male breast cancer patients treated between 1975 and 2005 at Eastern Virginia Medical School, Norfolk, VA. Demographic, pathologic, treatment, and survival information was collected. To facilitate comparison of trends, the patients were divided into two groups: Cohort A (1972–1991, previously reported) and Cohort B (1992–2005). Both cohorts included 28 male patients. Comparing the cohorts, no statistical differences were noted in median age, ethnicity, presenting symptoms, or progesterone receptor status. In Cohort A, 70 per cent of patients were estrogen receptor positive, compared with 100 per cent of Cohort B ( P = 0.02). Her2/neu was positive in three of five patients in Cohort B. There was a trend toward more conservative surgery, with no radical mastectomy or orchiectomy performed in Cohort B. Only two patients had sentinel lymph node mapping, both from Cohort B. Infiltrating ductal carcinoma was more prevalent in Cohort B ( P = 0.04). For Cohort A and B, 5-year survival was 43 per cent and 51 per cent, respectively, which was not statistically significant. For male breast cancer, radical mastectomy is no longer a common treatment modality. Male breast cancer of today is more hormonally responsive which may have important implications for therapy. Survival has not significantly improved over the previous 30 years. Compilation of multi-institutional data of male breast cancer is needed to advance the treatment of this uncommon disease.

Sign in / Sign up

Export Citation Format

Share Document